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Abstract
The University of Louisville Infectious Diseases Laboratory
followed the US Food and Drug Administration (FDA) Emer-
gency Use Authorization (EUA) guidance for developing a
molecular diagnostic test for SARS-CoV-2 to help address
the novel coronavirus pandemic. As a Clinical Laboratory Im-
provement Amendment ‘88 (CLIA) certified, high-complexity
clinical laboratory, the Infectious Diseases Laboratory chose
to use the Luminex ARIES® platform to evaluate a labora-
tory developed test. This instrument was already familiar to
the Infectious Diseases Laboratory and in use for molecular
diagnostic testing for pathogens causing atypical pneumo-
nia and two tick-borne pathogens. The FDA EUA guidance
for molecular diagnostic tests recommended limit of detec-
tion studies, inclusivity and exclusivity (specificity) analysis,
and validation with clinical samples to ensure that the per-
formance of the assay was acceptable for use as a molec-
ular diagnostic tool. Data obtained from these experiments
demonstrated acceptable performance per FDA guidance, as
well as for CLIA requirements. Thus, the real-time Reverse
Transcription PCR assay was implemented for diagnostic use
on March 27, 2020, and was of great benefit to the local com-
munity in responding to the pandemic.
Introduction
Coronaviruses are a large family of single-stranded
RNA viruses. Middle East Respiratory Syndrome
virus (MERS) and Severe Acute Respiratory Syndrome
virus (SARS) are two recent examples of novel coro-
naviruses that originated in animals and then spread
to humans.[1] The World Health Organization declared
that SARS-CoV-2 was a global pandemic on March 11,
2020.[2]
The US Food and Drug Administration’s (FDA) Emer-
gency Use Authorization (EUA) guidance for val-
idation of molecular assays for SARS-CoV-2, pub-
lished originally on February 29, 2020, allowed high-
complexity, CLIA-certified laboratories to validate
molecular assays and submit their data to the FDA for
review. The requirements initially set forth in the EUA
included establishing and verifying the limit of detec-
tion (LoD) or sensitivity, providing inclusivity and ex-
clusivity analysis (specificity), and performing analysis
on contrived clinical samples (30 negative and 30 posi-
tive) using the sample type(s) intended to be collected
and tested using the assay. As more clinical materials
positive for SARS-CoV-2 became available in the course
of the pandemic, the FDA updated the EUA guidance
(July 2020), requesting that laboratories use true clinical
samples rather than contrived samples to supplement
the initial data packet.
The University of Louisville Infectious Diseases Labo-
ratory is a CLIA-certified, high-complexity laboratory
with previous experience using laboratory-developed
tests on the Luminex ARIES® system.[3–6] To meet lo-
cal testing needs related to the pandemic, the Infectious
Diseases Laboratory partnered with Luminex Corpora-
tion to validate a SARS-CoV-2 real-time Reverse Tran-
scription PCR assay (RT-PCR) using a slight modifica-
tion of the CDC primer and probe sets targeting the
N1 and N3 nucleocapsid genes, as well as the human
RNase P gene, to create a multiplex molecular diag-
nostic assay. Data was compiled and published, along
with that of three other laboratories using the Luminex
ARIES® instrument, in a white paper in March 2020.[7]
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/10 1
ULJRI rt RT-PCR Assay for SARS-CoV-2 on the ARIES®
Table 1. SARS-CoV-2 Primer and Probe Information.a
Gene Target N1 N3 RNase P
Forward Primer
Primer ID 2019-nCoV N1-F 2019-nCoV N3-F RP-F
Sequence (5µ->3’) GACCCCAAAATCAGCGAAAT GGGAGCCTTGAATACACCAAAA AGATTTGGACCTGCGAGCG
Final concentration (µM) 0.2 0.2 0.1
Reverse Primer




Final concentration (µM) 0.2 0.2 0.1
Probe







Final concentration (µM) 0.3 0.3 0.1
a56-FAM = 5’ 6-FAM (Fluorescein), 3IABkFQ = 3’ Iowa Black® FQ, 56-TAMN = 5’ TAMRA (NHS Ester), 3IAbRQSp = 3’ Iowa Black® RQ, 5TYE665 = 5’ TYE™ 665
This report details our laboratory’s experience validat-
ing a molecular diagnostic assay to detect SARS-CoV-
2, using guidance for EUA from the US FDA, as well
as CLIA requirements for high-complexity testing. The
aim of this study was to provide data to support a
sample-to-answer testing option for laboratories to fa-
cilitate the sensitive and specific detection of SARS-
CoV-2 RNA in nasopharyngeal swab specimens.
Methods
Reagents
SARS-CoV-2 nucleocapsid specific N1 and N3 gene
targets, as well as the internal control human RNase
P gene target, primers and probe sets, were ob-
tained from Integrated DNA Technologies (Luminex
SARS-CoV-2 Panel 2, Integrated DNA Technologies,
Coralville, IA, USA) (Table 1). ARIES® TaqMan Exo+
Ready Mix® (Luminex Part number: 3698, Austin, TX)
and ARIES® extraction cassettes (Luminex Part num-
ber: 50-10026) were purchased, ready to use. Car-
rier RNA (cRNA) (QIAGEN Part number 1017647, Ger-
mantown, MD) prepared as 1 µg/µL solution in AVE
elution buffer (QIAGEN Part number 1026956), and
stored in the -20°C freezer prior to use.
Instrument used with Test
The SARS-CoV-2 real-time RT-PCR test was performed
on the Luminex ARIES® system, a sample-to-answer
instrument that can be used with both In Vitro Diag-
nostic PCR assays and Laboratory Developed Tests.
The ARIES® instrument required extraction cassettes,
ARIES® ReadyMix®, and Luminex ARIES® proprietary
SYNCTTM Software, as well as the User-Defined Proto-
col (UDP) application. No separate extraction instru-
ment was required for this assay. The instrument set-
tings for this protocol are shown in Table 2. To be con-
sidered positive for N1 detection, the Ct value had to be
less than 38; positive for N3, less than 37; and positive
for RNase P, less than 45 (Table 2). Following comple-
tion of the test run, the results were considered accept-
able if the assay passed quality control. Results were
then interpreted according to Table 3.
Luminex ARIES® SARS-CoV-2 real time RT-PCR assay
(modified CDC assay)
The original CDC real-time RT-PCR assay authorized
by the FDA required a separate extraction and PCR
step, as well as three separate wells for amplification
of each target (N1, N2, and RNase P). The Luminex
ARIES® did not require a separate extraction step, how-
ever. The CDC assay used the FAM dye and Black Hole
Quencher 1 (BHQ-1) on all three probes. The ARIES®
assay combined N1, N3, and RNaseP in one multiplex
reaction per cassette.[7] Since the targets were multi-
plexed in one cassette, the dyes on the probes needed to
be modified to facilitate differentiation of the three gene
targets. For the N1 target on the ARIES® assay, FAM
was used with a double quencher: ZENTM Internal
Quencher positioned between the ninth (9th) and tenth
(10th) nucleotide base in the oligonucleotide sequence
and Iowa Black® FQ (3IABkFQ) located at the 3’-end.
For the N3 target on ARIES®, the TAMRA dye was used
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Table 2. ARIES instrument settings for assay protocol channel, dye and
cut off values.
Channel Dye aCt Lower Ct Upper Gene Target
2 6FAM 1 38 N1
3 AP525 1 37 N3
6 AP662 1 45 RNase P
aCt=Cycle threshold.
Table 3. Interpretation of Results for the Luminex ARIES® Laboratory Developed Test.
N1 Result N3 Result RNase P Result Interpretation
Positive Positive Positive or Negative SARS-CoV-2 Detected
Positive Negative Positive Presumptive SARS-CoV-2 Positive; Retest x2
Negative Positive Positive Presumptive SARS-CoV-2 Positive; Retest x2
Negative Negative Positive SARS-CoV-2 Not Detected
Negative Negative Negative Invalid
with 3IAbRQSp and for the RNase P target, the TYE 665
dye was used with 3IAbRQSp. The cycling conditions
were modified on ARIES® due to instrument program-
ming limitations (shorter reverse transcription step,
no uracil-N-glycosylase/uracil DNA glycosylase step,
UNG). The cycling condition for the ARIES® SARS-
CoV-2 real-time RT-PCR assay were as follows:
• Reverse Transcription Step, 50°C for 7 minutes
• Enzyme Activation Step, 95°C for 2 minutes
• Amplification Step, including Denaturing and An-
nealing, 95°C for 15 seconds, 60°C for 22 seconds, 45
cycles
In contrast, the cycle conditions for the CDC SARS-
CoV-2 real-time RT-PCR assay were as follows:
• UNG Incubation Step, 25°C for 2 minutes
• RT Incubation Step, 50°C for 15 minutes
• Enzyme Activation Step, 95°C for 2 minutes
• Amplification Step, including Denaturing and An-
nealing, 95°C for 3 seconds, 55°C for 30 seconds, 45
cycles
Limit of Detection and Analytical Sensitivity
To determine the LoD of this real-time RT-PCR as-
say, quantitated amounts of heat-inactivated virus were
spiked into known negative nasopharyngeal swab
samples. Heat- inactivated viral culture fluid (Cata-
log # 0810587 CFHI-0.5mL, Zeptometrix, Buffalo, NY)
at a concentration of 1.50 X106 Tissue Culture Infective
Dose-50% (TCID50)/mL was tested using 10-fold serial
dilutions in known negative pooled nasopharyngeal
swab samples (concentrations ranging from 1.50x106 to
1.50x10-2). These dilutions were tested in triplicate. The
lowest concentration that gave positive results 100% of
the time was defined as the preliminary LoD. The final
LoD concentration was confirmed by testing 24 indi-
vidual extraction replicates at the preliminary LoD. The
FDA defined LoD as the lowest concentration at which
all 24 replicates were positive.
Specificity Studies (Inclusivity/Exclusivity)
An in silico analysis of published SARS-CoV-2 se-
quences using the SARS-CoV-2 assay’s primers and
probes was performed, with 100% being detected, and
published previously.[7] In addition, archived respi-
ratory pathogen–positive patient samples, previously
tested using the BioFire® Respiratory Pathogen Panel,
were tested with this assay. These included 11 different
respiratory virus–positive samples.
Stability Study
Two different positive patient nasopharyngeal samples
were chosen for the stability study. One fresh positive
sample chosen gave Ct values close to the established
LoD, while the other fresh sample gave Ct values below
the LoD. These two samples were stored in a refrigera-
tor at 4°C for a total of 8 days and were tested daily for
8 days to check the stability of the viral RNA.
Clinical Evaluation:
To assess the clinical performance of the real-time RT-
PCR assay, a total of 60 nasopharyngeal swab (clin-
ical) samples collected in saline or Universal Trans-
port Media (UTM) were tested on the ARIES®. Studies
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Position Sample ID Assay Name Test Result
B5 Positive sample UL 04.23.20 VC SARS-CoV-2 DETECTED
N1 RNA DETECTED
N3 RNA DETECTED
RNase P DNA DETECTED
Channel Channel Desc. Ct Channel Result
1 Not Used - -
2 N1 22.5 Detected
3 Not Used - -
4 N3 21.3 Detected
5 Not Used - -
6 RNase P 21.6 Detected
Figure 1. Positive SARS-CoV-2 real-time RT-PCR result. Sample data from ARIES instrument illustrating the amplification curve for the SARS-
CoV-2 specific N1 and N3 target and internal control RNase P.
Position Sample ID Assay Name Test Result
B6 Negative sample UL 04.23.20 VC SARS-CoV-2 Not Detected
N1 RNA not detected
N3 RNA not detected
RNase P DNA DETECTED
Channel Channel Desc. Ct Channel Result
1 Not Used - -
2 N1 ND Not Detected
3 Not Used - -
4 N3 ND Not Detected
5 Not Used - -
6 RNase P 30.0 Detected
Figure 2. Negative SARS-CoV-2 real-time RT-PCR result. Sample data from ARIES instrument illustrating the amplification curve for the internal
control RNase P.
comparing nasopharyngeal swabs collected in saline
versus UTM showed no difference in qualitative re-
sults for the CDC and ARIES® real-time RT-PCR assays
(data not shown). The first five SARS-CoV-2-positive
and the first five SARS-CoV-2-negative nasopharyngeal
swab patient samples collected in UTM were submit-
ted in early March 2020 to the Kentucky Division of
Laboratory Services in Frankfort, KY. In addition, the
Louisville Metro Public Health and Wellness Labora-
tory, Louisville, KY, provided 50 de-identified nasopha-
ryngeal swab (clinical) samples, collected in saline—
previously tested by the FDA EUA–approved CDC
real-time RT-PCR SARS-CoV-2 assay (gene targets N1,
N2, and RNaseP; three individual reactions)—to test on
the ARIES® instrument.
Data Analysis
Microsoft Excel was used to calculate averages and
standard deviations for Ct values from replicate exper-
iments, while MEDCALC Diagnostic Test Evaluation
was used to determine analytic sensitivity and speci-
ficity.[8] The User Defined Protocol (UDP) module in
the SYNCT® software (proprietary from Luminex) was
used to set assay parameters. The SYNCT® software
was installed on an external computer for detailed data
analysis and editing of Ct cutoff values. After complet-
ing data analysis and PCR assay validation, the cut-
off values were fixed and locked in the SYNCT® soft-
ware assay file. Next, the assay file was loaded on the
ARIES® instrument for subsequent diagnostic labora-
tory testing. Example results are shown in Figures 1
and 2. For a sample to be interpreted as negative or
positive for SARS-CoV-2, the following conditions had
to be met as shown in Tables 2 and 3:
(1) The internal control (RNaseP) for any NEGATIVE
sample must have a valid Ct value to exclude sam-
ple inhibition; however, it may be negative if N1
and N3 are positive.
(2) The sample must have Ct values in the established
range for each gene target if POSITIVE for N1, N3 or
RNaseP.
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Table 4. Limit of detection results for the SARS-CoV-2 real-time RT-PCR assay.
Sample Concentration N1 bCt Average N3 Ct Average RNase P Ct Average
aTCID50/mL (cSD, n=3) (SD, n=3) (SD, n=3)
1.50x105 13.63 (0.25) 13.20 (0.10) dND
1.50x104 17.63 (0.85) 17.07 (0.91) NDx2, 18.70 x1
1.50x103 21.37 (0.84) 20.93 (0.72) 21.50 (0.70)
1.50x102 23.97 (0.61) 23.57 (0.55) 23.53 (0.35)
1.50x101 28.67 (0.55) 27.23 (0.61) 25.17 (0.42)
e1.50x100 33.60 (0.56) 32.30 (0.46) 25.50 (0.26)
1.50x10-1 NDx2, 37.60x1 ND 27.93 (0.80)
1.50x10-2 ND ND 26.57 (0.31)
aTCID=Tissue Culture Infective Dose bCt=Cycle threshold cSD=Standard Deviation
dND=Not Detected eLimit of detection shown in bold




N1 Result N1 bCt
Average c(SD)













aTCID=Tissue Culture Infective Dose bCt=Cycle threshold cSD= Standard Deviation
Results
Initial data gathered for LoD studies in March 2020
were obtained using genomic blocks of DNA of the
novel coronavirus due to lack of viral materials early
in the pandemic. Using the Luminex ARIES® plat-
form, we were able to detect 300 DNA copies of the
SARS-CoV-2 nucleocapsid gene targets reproducibly,
using 20 replicate tests. Contrived nasopharyngeal
samples in UTM (created in the laboratory to mimic
clinical samples) were spiked with 1500 DNA copies of
SARS-CoV-2 synthetic material to further assess perfor-
mance. As more viral RNA sources became available,
the LoD studies were repeated with heat-inactivated
culture fluid containing SARS-CoV-2. The LoD estab-
lished with this viral material was 1.5 TCID50/mL, us-
ing 24 replicates to confirm this virus concentration
(Tables 4 and 5), thus serving as precision data as
well. Specificity experiments demonstrated no cross-
reactivity with 11 other respiratory viruses, including
the four endemic coronaviruses (Table 6). Testing daily
over an 8-day period demonstrated that RNA was de-
tectable the entire time, with little variability in original
and final Ct values (Table 7).
Per the FDA EUA guidance, a total of 60 clinical sam-
ples, 30 positive and 30 negative, were tested using the
ARIES® platform. In March 2020, the first five posi-
tive clinical samples and the first five negative clini-
cal samples were confirmed by the Kentucky Division
of Laboratory Services in Frankfort, KY, the state pub-
lic health laboratory, using the EUA approved, CDC
real-time RT-PCR novel coronavirus assay (data not
shown). In July 2020, 25 deidentified positive sam-
ples and 25 deidentified negative samples were pro-
vided by the Louisville Metro Public Health and Well-
ness Laboratory, a local, public health, CLIA-certified,
high-complexity laboratory, using the same real-time
RT-PCR assay as the Kentucky Division of Laboratory
Services. All of these results agreed 100% as well, giv-
ing 100% analytical sensitivity (95% Confidence Inter-
val 88.43 to 100) and 100% analytical specificity (95%
Confidence Interval 88.43 to 100). Remarkably, despite
the modifications of the CDC assay and differing real-
time RT-PCR platforms, the accuracy was 100% for all
25 sample results. Furthermore, the Ct values for N1
were very similar (less than three Ct units’ difference)
for both assays on all samples except #13, #21 and #22
(Table 8, rows in bold).
Discussion
Our laboratory was able to successfully implement a
real-time RT-PCR assay to detect SARS-CoV-2 in na-
sopharyngeal samples on the Luminex ARIES® plat-
form by March 27, 2020. The assay performance data
met both the FDA EUA requirements and CLIA stan-
dards for a diagnostic assay by reproducibly detecting
the N1 and N3 gene targets at 1.5 TCID50/mL. Eval-
uation of clinical samples achieved 100% accuracy, as
well as acceptable analytical sensitivity and specificity
for nasopharyngeal swabs. The strengths of this report
include following a standardized method validation
guidance document from the FDA and supplement-
ing with experiments to meet CLIA requirements for a
laboratory-developed test. Results from two indepen-
dent public health laboratories using the CDC EUA-
approved novel coronavirus assay confirmed equiva-
lent performance of the ARIES® multiplex real-time RT-
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Table 6. Specificity studies with known respiratory pathogen positive samples.
Sample Expected Test Result N1 Result N1 aCt N3 Result N3 Ct RNase P Result RNase P Ct
A1 RSV Negative bND Negative ND Positive 26
A2 FluA H3 Negative ND Negative ND Positive 24.4
A3 Para 2 Negative ND Negative ND Positive 28.6
A4 FluB Negative ND Negative ND Positive 26.1
A5 Corona OC43 Negative ND Negative ND Positive 33.6
A6 Rhino/Enterovirus Negative ND Negative ND Positive 29.3
A7 Para 4 Negative ND Negative ND Positive 29.5
A8 Para 3 Negative ND Negative ND Positive 28.9
A9 Corona 229 Negative ND Negative ND Positive 26.1
A10 Corona NL63 Negative ND Negative ND Positive 25.2
A11 Corona HKU-1 Negative ND Negative ND Positive 26.2
aCt=Cycle threshold bND=Not Detected
Table 7. Stability assay for SARS-CoV-2 rt RT-PCR assay.
Sample N1 Result N1 aCt
Average b(SD)















aCt=Cycle threshold bSD=Standard Deviation
PCR assay. The advantages of using the ARIES® plat-
form include a combined extraction and detection pro-
cess and a multiplex PCR assay in a closed system.
Furthermore, a true internal control—a human RNaseP
primer/probe set—was included to detect sample inhi-
bition, as well as proper extraction of the sample. For
diagnostic laboratories, the availability of a sensitive
and specific test for SARS-CoV-2 in a closed system,
giving results within two hours, greatly improves the
testing process and significantly limits potential con-
tamination.
During the pandemic, there has been a clear recogni-
tion that laboratory testing is central to helping control
and prevent the spread of the disease by identifying in-
fected patients and starting treatment.[9] The ability to
have a test available by March 27, 2020, to support the
pandemic response in our community was critical since
the initial priority population was health care workers
from a large health care system in Louisville, KY. As
the needs of the community changed, we were able to
make testing available to health care systems for inpa-
tients, those scheduled for elective surgery who had
been postponed, employees of local large businesses,
nursing home staff, and people who traveled via air-
lines that needed COVID-19 diagnostic results. Hav-
ing an accurate test with a two-hour turnaround time
proved beneficial to these populations and organiza-
tions.
Limitations of the study primarily involved supply
chain issues, leading to a more limited validation pro-
cess. For example, early in the pandemic, there was
a lack of quantitated RNA control materials derived
from the novel coronavirus that could be safely han-
dled in a BSL-2 laboratory. Subsequently, as more labo-
ratories brought on molecular testing, shortages in viral
transport media, swabs and primer/probe sets became
limiting, affecting our ability to test contrived or true
clinical samples. Finally, most laboratories experienced
shortages of consumables, especially plastics used for
molecular testing, and being placed on allocation for
PCR kits. For our laboratory, these shortages limited
the validation to only one respiratory sample type, the
gold-standard nasopharyngeal swab. For a clinical lab-
oratory, it would have been preferable to validate mul-
tiple sample types.
Future studies will include testing the sensitivity of the
ARIES® assay when pooling respiratory samples and
validating other common upper and lower respiratory
tract samples to benefit the local health care commu-
nity. Another planned study involves comparison of
Ct values to viral culture results through a collabora-
tion with a local laboratory with viral culture and BSL-
3 capabilities. Finally, we have conducted preliminary
studies to determine assay performance for oropha-
ryngeal versus nasopharyngeal samples, as well as
self-collected nasal swabs versus provider-collected na-
sopharyngeal swabs. We also compared the laboratory-
developed test for SARS-CoV-2 to the EUA-approved
In Vitro Diagnostic version for the ARIES® platform of-
fered by Luminex Corporation.
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Table 8. Accuracy results for positive clinical samples provided by the Louisville Metro Public Health
and Wellness Laboratory, Louisville, KY.
University of Louisville Louisville Metro Public Health
Infectious Diseases Laboratory and Wellness Laboratory
Specimen # N1 aCt N3 Ct RNase P Ct N1 Ct N2 Ct RNase P Ct
POS 1 27.1 26.4 26.3 27.62 26.48 31.11
POS 2 26 25.2 24.7 24.04 23.12 31.43
POS 3 26.5 25.5 25.1 25.42 24.26 28.65
POS 4 22.6 22.8 22.9 25.13 23.56 29.58
POS 5 23.2 22.5 22.5 20.46 19.42 28.39
POS 6 34.7 34.1 29.3 27.93 28.14 25.92
POS 7 26.5 25.5 25.7 25.22 24.16 28.37
POS 8 34.1 33.3 29.1 32.14 31.55 28.77
POS 9 17 17.1 bND 17.87 15.97 29.65
POS 10 23.3 22.3 22.5 19.33 18.51 29.97
POS 11 35.9 35.7 29.5 36.21 32.93 28.58
POS 12 33.5 32.5 29.8 34.67 33.03 26.58
cPOS 13 22 22.1 ND 15.28 15.49 26.15
POS 14 22.5 21.7 22.4 22.4 21.6 28.69
POS 15 22.7 21.5 21.3 22.21 20.26 30.85
POS 16 25.5 24.3 24.3 24.28 ND 30.81
POS 17 22.9 22.2 23.1 21.09 20.31 27.14
POS 18 25 25.5 ND 22.19 22.3 26.95
POS 19 20.9 20.1 ND 21.9 20.6 31.12
POS 20 30.7 29.9 28.2 30.38 29.21 28.31
cPOS 21 34.3 33.3 27.2 ND 33.67 30.73
cPOS 22 32.7 31.2 29.3 25.22 24.16 28.37
POS 23 18.6 17.7 ND 18.18 17.97 27.79
POS 24 26.7 25.9 25.6 23.95 23.05 27.68
POS 25 29.9 29.1 27.9 28.33 28.11 30.68
aCt=Cycle threshold bND=Not Detected cSignificant differences in Ct values shown in
bold
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